Physician profile
Richard E Matte
NPI 1700863651
$1,515.03
in general payments reported to CMS, 2019-2025
9 companies · $544 in 2025
The $544 reported for 2025 was more than what 97% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $119 · 2023: $354 · 2024: $337 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $356.66 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $295.02 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Intuitive Surgical, INC. | $220.51 | 2023 | Da Vinci Surgical System |
| Intercept Pharmaceuticals, INC. | $189.11 | 2022-2024 | Ocaliva |
| Globus Medical, INC. | $161.44 | 2021 | |
| Stryker Corporation | $99.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.57 | 2023-2025 | Xifaxan |
| Lilly USA, LLC | $61.13 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $57.87 | 2024-2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Matte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.